niflumic acid [Ligand Id: 2439] activity data from GtoPdb and ChEMBL
Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL63323 (Niflugel, Niflumic acid, NSC-758196, UP 83, UP-83) |
|---|
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| COX-1 /Cyclooxygenase-1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL221] [GtoPdb: 1375] [UniProtKB: P23219] | ||||||||
| ChEMBL | DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) | B | 5.97 | pIC50 | 1064 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| COX-2 /Cyclooxygenase-2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL230] [GtoPdb: 1376] [UniProtKB: P35354] | ||||||||
| ChEMBL | DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) | B | 6.04 | pIC50 | 918 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| dihydroorotate dehydrogenase (quinone)/Dihydroorotate dehydrogenase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1966] [GtoPdb: 2604] [UniProtKB: Q02127] | ||||||||
| ChEMBL | Inhibition of human recombinant DHODH | B | 4.77 | pIC50 | 17000 | nM | IC50 | ACS Med Chem Lett (2016) 7: 1112-1117 [PMID:27994748] |
| GPR35/G-protein coupled receptor 35 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1293267] [GtoPdb: 102] [UniProtKB: Q9HC97] | ||||||||
| ChEMBL | Displacement of [3H]PSB-13253 from human recombinant GPR35 exprssed in CHO cells by liquid scintillation counting analysis | B | 5.44 | pKi | 3610 | nM | Ki | J Med Chem (2013) 56: 7084-7099 [PMID:23888932] |
| ChEMBL | Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins | B | 5.89 | pIC50 | 1280 | nM | IC50 | ACS Med Chem Lett (2012) 3: 165-169 [PMID:24900447] |
| ChEMBL | Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay | F | 4.4 | pEC50 | 40200 | nM | EC50 | ACS Med Chem Lett (2012) 3: 165-169 [PMID:24900447] |
| ChEMBL | Agonist activity at C-terminal beta-galactosidase tagged human recombinant GPR35 expressed in CHO cells after 90 mins by beta-arrestin recruitment assay | B | 4.51 | pEC50 | 30800 | nM | EC50 | J Med Chem (2013) 56: 7084-7099 [PMID:23888932] |
| ChEMBL | Agonist activity at human GPR35 expressed in HEK293T cells at 5 uM by EYPF-based beta-arrestin-2 luciferase reporter gene assay | B | 4.82 | pEC50 | 15000 | nM | EC50 | J Med Chem (2013) 56: 7084-7099 [PMID:23888932] |
| ChEMBL | Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay | F | 5.94 | pEC50 | 1150 | nM | EC50 | ACS Med Chem Lett (2012) 3: 165-169 [PMID:24900447] |
| ChEMBL | Agonist activity at human GPR35 by DMR assay | B | 5.95 | pEC50 | 1110 | nM | EC50 | J Med Chem (2013) 56: 7084-7099 [PMID:23888932] |
| TEA domain transcription factor 4/Transcriptional enhancer factor TEF-3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4295828] [GtoPdb: 3243] [UniProtKB: Q15561] | ||||||||
| ChEMBL | Binding affinity to human His-tagged TEAD4 YBD (217 to 434 residues) expressed in Escherichia coli BL21(DE3) after 30 mins by ITC assay | B | 4.55 | pKd | 28000 | nM | Kd | J Med Chem (2018) 61: 5057-5072 [PMID:29251924] |
| ChEMBL | Binding affinity to N-terminal His6-tagged human TEAD4 YAP binding domain (217 to 434 residues) expressed in Escherichia coli C43 (DE3) cells by ITC method | B | 4.55 | pKd | 28000 | nM | Kd | J Med Chem (2020) 63: 11972-11989 [PMID:32907324] |
| ChEMBL | Binding affinity to His-tagged TEAD4 YPD domain (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) by isothermal titration calorimetry | B | 4.55 | pKd | 28000 | nM | Kd | Eur J Med Chem (2021) 226: 113835-113835 [PMID:34509860] |
| ChEMBL | Inhibition of CPM binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by CPM addition and measured after 1 hr by fluorescence assay | B | 4.38 | pIC50 | 41900 | nM | IC50 | J Med Chem (2020) 63: 11972-11989 [PMID:32907324] |
| ChEMBL | Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay | B | 5.23 | pIC50 | 5900 | nM | IC50 | J Med Chem (2020) 63: 11972-11989 [PMID:32907324] |
| Transcription factor SOX-18 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4523228] [UniProtKB: P43680] | ||||||||
| ChEMBL | Inhibition of mouse SOX18 expressed in African green monkey COS7 cells assessed as reduction in SOX18 transcriptional activity by luciferase reporter gene assay | B | 4.3 | pIC50 | 50500 | nM | IC50 | WO-2018112545-A1. Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases (2018) |
| transthyretin/Transthyretin in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3194] [GtoPdb: 2851] [UniProtKB: P02766] | ||||||||
| ChEMBL | Binding affinity to TTR (unknown origin) by isothermal titration calorimetric analysis | B | 6.59 | pKd | 260 | nM | Kd | J Med Chem (2015) 58: 6507-6515 [PMID:26214366] |
| ChEMBL | FP Assay: The FP assay was then adapted for HTS and used to screen ~120,000 small molecule library for compounds that displaced probe 5 from the T4 binding of TTR. The FP assay was performed in 384-well plate using very low concentration of probe 5 (1.5 nM) and TTR (50 nM) in a 10 μL assay volume. A detergent (0.01% Triton-X100) was added to the assay buffer to avoid any false positive hits from promiscuous, aggregate-based inhibitors. The assay demonstrated robust performance, with a very good dynamic range (−70-230 mP) and a Z′ factor in the range of 0.57-0.78 (FIGS. 4A and 4B). "Hits" were defined as compounds that resulted in at least 50% decrease in fluorescence polarization and demonstrated relative fluorescence between 70 and 130%. Many fluorescence quenchers and enhancers having less than 70% and greater than 130% total fluorescence relative to a control, respectively, were excluded from the hit list. 200 compounds were designated as positive hits (0.167% hit rate). | B | 6.54 | pIC50 | 289 | nM | IC50 | US-8877795-B2. Identification of stabilizers of multimeric proteins (2014) |
| KNa1.2 in Human [GtoPdb: 386] [UniProtKB: Q6UVM3] | ||||||||
| GtoPdb | - | - | 8.68 | pEC50 | 2.1 | nM | EC50 |
J Gen Physiol (2010) 135: 275-95 [PMID:20176855]; Mol Pharmacol (2012) 82: 795-802 [PMID:22851714] |
| TRPA1 in Rat [GtoPdb: 485] [UniProtKB: Q6RI86] | ||||||||
| GtoPdb | Two electrode voltage clamp | - | 3.3 | pEC50 | - | - | - | Pflugers Arch (2010) 459: 579-92 [PMID:19888597] |
| ClC-Ka in Human [GtoPdb: 700] [UniProtKB: P51800] | ||||||||
| GtoPdb | - | - | 5 | pEC50 | 10000 | nM | EC50 | |
| ClC-Kb in Human [GtoPdb: 701] [UniProtKB: P51801] | ||||||||
| GtoPdb | - | - | 5 | pEC50 | 10000 | nM | EC50 | |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]
